PSMA PET-directed surgical metastasis-directed therapy in metachronous prostate cancer.
Cent European J Urol
; 76(3): 182-185, 2023.
Article
in En
| MEDLINE
| ID: mdl-38045775
ABSTRACT
We present the case of a patient who underwent an open radical prostatectomy with pelvic lymph node dissection (Gleason 4+3, pT3a pN1 R0) in March 2017. In November 2020, prostate-specific membrane antigen (PSMA)-radioguided salvage lymph node dissection was planned due to a single left para-rectal lymph node at a [68Ga] Ga-PSMA-I&T PET. In January 2022, the [68Ga] Ga-PSMA-I&T PET showed an isolated liver lesion. Biopsy confirmed prostate adenocarcinoma. A liver segmentectomy was performed. A complete biochemical response was reported until the last follow-up (December 2022). Prostate-specific membrane antigen positron emission tomography (PSMA PET)-directed metastasis-directed therapy may be an effective treatment in selected cases, allowing a benefit in the oncological outcome.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Cent European J Urol
Year:
2023
Document type:
Article
Affiliation country:
Germany